Clinical Trial: Interaction Between Nalbuphine and Morphine in PCA

This study is currently recruiting patients.
Verified by National Taiwan University Hospital June 2005

Sponsored by: National Taiwan University Hospital
Information provided by: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT00155233

Purpose

  1. Nalbuphine is opioid mu receptro antagonist and kappa receptor agonist
  2. This study was designed to investigate the interaction between nalbuphine and morphine
Condition Intervention Phase
Postoperative Pain
 Drug: Nalbuphine and morphine
Phase IV

MedlinePlus related topics:  Pain

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Safety/Efficacy Study

Official Title: Interaction Between Nalbuphine and Morphine in Postoperative PCA for Gynecologic Patients

Further Study Details: 
Primary Outcomes: analgesic effect
Secondary Outcomes: incidence of opioid-related side effects
Expected Total Enrollment:  200

Study start: January 2005

  1. Nalbuphine is opioid mu receptro antagonist and kappa receptor agonist
  2. This study was designed to investigate the interaction between nalbuphine and morphine
  3. The analgesic effect and opioid-related side effects will be investigated

Eligibility

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Female
Criteria

Inclusion Criteria:

  1. Age 18-65 y/o
  2. Female patients of ASA physical status I to III
  3. Scheduled for elective abdominal hysterectomy, myomectomy, or excision of ovarian tumor

Exclusion Criteria:

  1. Patients with a definite diagnosis of chronic pain syndrome, psychiatric disorders, or drug abuse (include opioids, NSAIDs, sedatives, antidepressants)
  2. Intraoperative fentanyl use > 3 μg/kg
  3. Patients with definite diagnosis of esophageal reflux syndrome
  4. Use of sedatives, antiemetics, or antipruritics within 24 hours before operation
  5. Surgery > 4 hours or laparoscopy surgery

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00155233


Taiwan
      National Taiwan University Hospital, Taipei,  100,  Taiwan; Recruiting
Yu Chang Yeh, MD   cooltony@ha.mc.ntu.edu.tw 
Wei-Zen Sun, MD,  Principal Investigator

Study chairs or principal investigators

Wei-Zen Sun, MD,  Principal Investigator,  National Taiwan University Hospital   

More Information

Study ID Numbers:  931002
Last Updated:  September 9, 2005
Record first received:  September 8, 2005
ClinicalTrials.gov Identifier:  NCT00155233
Health Authority: Taiwan: Department of Health
ClinicalTrials.gov processed this record on 2005-09-13

Resources




Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us